Michael D Devous

List of Publications by Year
in descending order

80 papers	4,751 citations	147726 31 h-index	133188 59 g-index
93 all docs	93 docs citations	93 times ranked	5516 citing authors

#	Article	IF	Citations
1	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.4	603
2	Regional profiles of the candidate tau PET ligand¹⁸F-AV-1451 recapitulate key features of Braak histopathological stages. Brain, 2016, 139, 1539-1550.	3.7	372
3	Four distinct trajectories of tau deposition identified in Alzheimerâ€™s disease. Nature Medicine, 2021, 27, 871-881.	15.2	354
4	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
5	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain, 2017, 140, aww334.	3.7	257
6	Positron Emission Tomography Imaging With [¹⁸F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurology, 2020, 77, 829.	4.5	244
7	Risk Factors for Î²-Amyloid Deposition in Healthy Aging. JAMA Neurology, 2013, 70, 600.	4.5	216
8	Tau Positron-Emission Tomography in Former National Football League Players. New England Journal of Medicine, 2019, 380, 1716-1725.	13.9	165
9	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimerâ€™s disease dementia. Brain, 2019, 142, 1723-1735.	3.7	156
10	¹⁸Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	2.8	148
11	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 4.	3.0	134
12	Distinctive disruption patterns of white matter tracts in Alzheimer's disease with full diffusion tensor characterization. Neurobiology of Aging, 2012, 33, 2029-2045.	1.5	104
13	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's and Dementia, 2018, 14, 1565-1571.	0.4	98
14	Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 373-379.	1.2	90
15	Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults. JAMA Neurology, 2017, 74, 830.	4.5	87
16	Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. NeuroImage, 2012, 62, 1-8.	2.1	84
17	Kinetics of the Tau PET Tracer ¹⁸F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1535-1542.	2.8	84
18	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	1.2	80

#	Article	IF	Citations
19	Risk factors for mild cognitive impairment among Mexican Americans. Alzheimer's and Dementia, 2013, 9, 622.	0.4	79
20	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. Journal of Nuclear Medicine, 2018, 59, 944-951.	2.8	73
21	Biomarkers of Alzheimer's Disease Among Mexican Americans. Journal of Alzheimer's Disease, 2013, 34, 841-849.	1.2	69
22	Cortico-Amygdala Coupling as a Marker of Early Relapse Risk in Cocaine-Addicted Individuals. Frontiers in Psychiatry, 2014, 5, 16.	1.3	63
23	Dopamine efflux in response to ultraviolet radiation in addicted sunbed users. Psychiatry Research - Neuroimaging, 2016, 251, 7-14.	0.9	62
24	A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. Journal of Nuclear Medicine, 2015, 56, 1736-1741.	2.8	61
25	Testâ€“Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. Journal of Nuclear Medicine, 2018, 59, 937-943.	2.8	55
26	Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 1351-1364.	1.2	48
27	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry, 2022, 79, 464.	6.0	47
28	The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans. Journal of Alzheimer's Disease, 2013, 34, 701-706.	1.2	45
29	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	1.3	42
30	Topographic staging of tau positron emission tomography images. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 221-231.	1.2	41
31	Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 825-837.	3.3	40
32	Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dementia and Geriatric Cognitive Disorders, 2017, 44, 129-143.	0.7	35
33	Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach. BMC Bioinformatics, 2016, 17, 357.	1.2	34
34	Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. Alzheimer's and Dementia, 2017, 13, 1117-1124.	0.4	31
35	Amyloid deposition in younger adults is linked to episodic memory performance. Neurology, 2016, 87, 2562-2566.	1.5	27
36	Technical Considerations in Brain Amyloid PET Imaging with ¹⁸F-Florbetapir. Journal of Nuclear Medicine Technology, 2015, 43, 175-184.	0.4	26

#	Article	IF	Citations
37	Comparison of relative cerebral blood flow maps using pseudoâ€continuous arterial spin labeling and single photon emission computed tomography. NMR in Biomedicine, 2012, 25, 779-786.	1.6	25
38	The effect of betaâ€amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal. Human Brain Mapping, 2015, 36, 2514-2526.	1.9	25
39	Quantification of 18F-florbetapir PET: comparison of two analysis methods. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 725-732.	3.3	25
40	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimerâ€™s disease pathology: a clinicopathological study. EJNMMI Research, 2020, 10, 65.	1.1	25
41	Altered Neural Processing of Threat in Alcohol-Dependent Men. Alcoholism: Clinical and Experimental Research, 2013, 37, 2029-2038.	1.4	23
42	Tau Subtypes of Alzheimerâ€™s Disease Determined in vivo Using Flortaucipir PET Imaging. Journal of Alzheimer's Disease, 2019, 71, 1037-1048.	1.2	22
43	Parametric methods for [¹⁸F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 365-373.	2.4	22
44	A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 70, 163-170.	1.2	21
45	O4â€08â€06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR Fâ€18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A Î²â€AMYLOID PLAQUEâ€SPECIFIC ANTIBODY, IN ALZHEIMERâ€™S DISEASE (AD). Alzheimer's and Dementia, 2016, 12, P352.	0.4	19
46	Striatalâ€“limbic activation is associated with intensity of anticipatory anxiety. Psychiatry Research - Neuroimaging, 2012, 204, 123-131.	0.9	17
47	Interaction between early life stress and alcohol dependence on neural stress reactivity. Addiction Biology, 2015, 20, 523-533.	1.4	17
48	Caudolateral orbitofrontal regional cerebral blood flow is decreased in abstinent cocaineâ€addicted subjects in two separate cohorts. Addiction Biology, 2012, 17, 1001-1012.	1.4	11
49	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1495.	5.8	11
50	P4-316: MEASURING CHANGE IN BETA-AMYLOID BURDEN OVER TIME USING FLORBETAPIR-PET AND A SUBCORTICAL WHITE MATTER REFERENCE REGION. , 2014, 10, P902-P902.		8
51	ICâ€Pâ€022: Conversion of Amyloid Quantitation With Florbetapir Suvr to The Centiloid Scale. Alzheimer's and Dementia, 2016, 12, P25.	0.4	6
52	Differences in regional cerebral blood flow response to a 5HT3 antagonist in earlyâ€and lateâ€onset cocaineâ€dependent subjects. Addiction Biology, 2014, 19, 250-261.	1.4	5
53	ICâ€Pâ€183: EMPLOYING EARLY UPTAKE DATA FROM F18â€FLORBETAPIR SCANS AS AN ESTIMATE OF REGIONAL CEREBRAL BLOOD FLOW: COMPARISON TO F18â€FDG. Alzheimer's and Dementia, 2014, 10, P102.	0.4	5
54	IC-O3-01: The Centiloid Scale: Standardization of amyloid imaging measures. , 2013, 9, P8-P8.		4

#	Article	IF	Citations
55	123I-Iofluopane Single-Photon Emission Computed Tomography as an Imaging Biomarker of Pre-Synaptic Dopaminergic System after Moderate-to-Severe Traumatic Brain Injury. Journal of Neurotrauma, 2020, 37, 2113-2119.	1.7	4
56	DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		3
57	[O5â€“01â€“01]: PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD. Alzheimer's and Dementia, 2017, 13, P1452.	0.4	3
58	P4-314: TEST-RETEST DATA FOR THE TAU PET IMAGING AGENT 18F-AV-1451 (PREVIOUSLY, 18F-T807). , 2014, 10, P901-P901.		2
59	O1â€07â€06: Hippocampal sparing and limbic predominant tau subtypes of Alzheimer's disease determined in vivo using [18F]â€AVâ€1451 PET imaging. Alzheimer's and Dementia, 2015, 11, P144.	0.4	2
60	O1-07-05: IMPACT OF B-AMYLOID BURDEN ON BRAIN PERFUSION AND VASCULAR REACTIVITY IN NORMAL AGING. , 2014, 10, P143-P144.		1
61	IC-P-171: Region-dependent kinetics of the Tau PET tracer [18 F]-AV-1451 (T807). , 2015, 11, P113-P113.		1
62	[P2â€“383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER's DISEASE PATHOLOGY: A PILOT CLINICOâ€PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P776.	0.4	1
63	DTâ€01â€05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSYâ€VALIDATED CASES. Alzheimer's and Dementia, 2019, 15, P1486.	0.4	1
64	P4-136: DOES HIPPOCAMPAL VOLUME PREDICT POSITIVE AMYLOID STATUS ON FLORBETAPIR-PET IN HEALTHY CONTROLS AND PRODROMAL STAGES OF ALZHEIMER'S DISEASE?. , 2014, 10, P836-P837.		0
65	P4-311: IS FLORBETAPIR-PET OCCIPITAL SUVR A LATE BIOMARKER IN MILD OR MODERATE AD DEMENTIA AS COMPARED TO HIPPOCAMPAL VOLUME?. , 2014, 10, P900-P900.		0
66	IC-01-02: AMYLOID ACCUMULATION IN EARLY AND MIDDLE ADULTHOOD: THE IMPACT OF LIFE EXPERIENCE. , 2014, 10, P1-P1.		0
67	P4-306: EFFECTS OF IN VIVO AMYLOID BURDEN ON COGNITION IN HEALTHY ADULTS AGED 30 TO 89: INITIAL LONGITUDINAL RESULTS ACROSS 3.5 YEARS FROM THE DALLAS LIFESPAN BRAIN STUDY. , 2014, 10, P897-P898.		0
68	IC-P-030: Comparison of reference regions for improved detection of change in florbetapir PET from phase 3 solanezumab trials. , 2015, 11, P29-P30.		0
69	P4-259: Relationships between cognitive assessments and spatial distribution of neuropathological tau as assessed by 18 F AV-1451 PET scanning. , 2015, 11, P881-P881.		0
70	IC-P-165: Understanding the topology of 18 F-AV-1451 (also known as T807) PET tau images in Alzheimer's disease. , 2015, 11, P110-P111.		0
71	ICâ€Pâ€196: Quantification of TAU Load Using [¹⁸F]AVâ€1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
72	O4â€02â€05: The Relationship of [18F]Avâ€1451 Pet Tau Images to Changes in Cognition Over Time. Alzheimer's and Dementia, 2016, 12, P336.	0.4	0

#	Article	IF	Citations
73	IC-P-134: Differentiating Preclinical Alzheimerâ€™s Disease from Normal Aging: The Effects of Age and Amyloid on Cognitive Decline Over 3.5 Years. , 2016, 12, P100-P100.		0
74	O1â€07â€02: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]â€AVâ€1451 (T807) PET Studies. Alzheimer's and Dementia, 2016, 12, P189.	0.4	0
75	O4-07-01: Evolution of [18 F]Av-1451 Pet Tau Signal: Interim Analysis of an 18-Month Phase 2 Study. , 2016, 12, P347-P347.		0
76	[ICâ€01â€“04]: A ROBUST, SIMPLIFIED BRAAKâ€TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR Fâ€18 TAU PET IMAGES. Alzheimer's and Dementia, 2017, 13, P3.	0.4	0
77	[P4â€“227]: THE ASSOCIATION OF TAU BURDEN IN CEREBRAL LOBES AND FUNCTIONAL BRAIN NETWORKS WITH PERFORMANCE IN DIFFERENT COGNITIVE DOMAINS. Alzheimer's and Dementia, 2017, 13, P1357.	0.4	0
78	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.4	0
79	[P4â€“530]: MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER's DISEASE SPECTRUM USING [18F]â€FLORTAUCIPIR PET IMAGING. Alzheimer's and Dementia, 2017, 13, P1552.	0.4	0
80	ICâ€Pâ€216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITIONâ€3 TRIAL. Alzheimer's and Dementia, 2018, 14, P177.	0.4	0